دورية أكاديمية
Evaluation of the health-related quality of life using the 36-item short form health survey in patients with chronic hepatitis C receiving pegylated interferon/ribavirin/telaprevir triple treatment.
| العنوان: | Evaluation of the health-related quality of life using the 36-item short form health survey in patients with chronic hepatitis C receiving pegylated interferon/ribavirin/telaprevir triple treatment. |
|---|---|
| المؤلفون: | MITSUYUKI SUZUKI, TORU ISHIKAWA, AI SAKUMA, SATOSHI ABE, HIROKO ABE, FUJIKO KOYAMA, TOMOMI NAKANO, AYA UEKI, HIROHITO NOGUCHI, ERINA HASEGAWA, SHIORI YAMAGATA, MIKI KOBAYASHI, KAZUTAKA OHASHI, HIROSHI HIROSAWA, TAKAKO FUKAZAWA, YUKA MARUYAMA, TOSHIAKI YOSHIDA |
| المصدر: | Experimental & Therapeutic Medicine; Nov2016, Vol. 12 Issue 5, p3353-3358, 6p |
| مصطلحات موضوعية: | CHRONIC hepatitis C, INTERFERONS, RIBAVIRIN, TELAPREVIR, HEALTH surveys, THERAPEUTICS |
| مستخلص: | The rate of sustained virologic response (SVR) has increased in patients with chronic hepatitis C (CHC; genotype 1) since triple treatment with pegylated interferon (PEG-IFN), ribavirin (RBV) and telaprevir (TVR) was included in Japanese health insurance. However, side effects such as high-grade anemia and skin disorders means it is important to investigate the extent to which quality of life (QOL) is maintained during treatment. The impact on health-related (HR) QOL, as a result of TVR-based triple treatment was investigated long-term (48 weeks) in 34 patients (18 men, 16 women) following TVR-based triple treatment, using the 36-item short form health survey (SF-36). While scores for physical health were significantly lower during treatment, an improvement was seen in patients who showed complete response to treatment from 12 weeks following treatment (P<0.05). HRQOL improved significantly following completion of TVR-based triple treatment in these complete-responders, with higher scores compared with those prior to treatment. Anemia and skin symptoms appeared frequently during treatment and scores for physical health dropped. Particular care needs to be taken in regards to the management of side effects during TVR treatment. Further evaluations using the SF-36 may help in controlling doses to achieve SVR. [ABSTRACT FROM AUTHOR] |
| Copyright of Experimental & Therapeutic Medicine is the property of Spandidos Publications UK Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| قاعدة البيانات: | Complementary Index |
Full Text Finder كن أول من يترك تعليقا!